JP2009536918A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536918A5 JP2009536918A5 JP2008557842A JP2008557842A JP2009536918A5 JP 2009536918 A5 JP2009536918 A5 JP 2009536918A5 JP 2008557842 A JP2008557842 A JP 2008557842A JP 2008557842 A JP2008557842 A JP 2008557842A JP 2009536918 A5 JP2009536918 A5 JP 2009536918A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- hydroxy
- cycloalkyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- -1 C 1 -C 4 alkoxy Chemical group 0.000 claims description 156
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- 229910052799 carbon Inorganic materials 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000003277 amino group Chemical group 0.000 claims description 13
- 150000001721 carbon Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 13
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 12
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical class 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims 4
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 claims 3
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 208000008035 Back Pain Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- PLZBVENLOXXNIQ-UHFFFAOYSA-N 1-[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)benzimidazol-5-yl]sulfonylcyclopropane-1-carboxamide Chemical compound CC(C)(C)CC1=NC2=CC(S(=O)(=O)C3(CC3)C(N)=O)=CC=C2N1CC1CC1 PLZBVENLOXXNIQ-UHFFFAOYSA-N 0.000 claims 1
- LKUMJNATHAMXPC-UHFFFAOYSA-N 1-[2-[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)benzimidazol-5-yl]sulfonyl-2-methylpropyl]-3-methylurea Chemical compound CC(C)(C)CC1=NC2=CC(S(=O)(=O)C(C)(C)CNC(=O)NC)=CC=C2N1CC1CC1 LKUMJNATHAMXPC-UHFFFAOYSA-N 0.000 claims 1
- UODSBEAPZZOMEY-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)benzimidazol-5-yl]sulfonyl-2-methylpropanamide Chemical compound CC(C)(C)CC1=NC2=CC(S(=O)(=O)C(C)(C)C(N)=O)=CC=C2N1CC1CC1 UODSBEAPZZOMEY-UHFFFAOYSA-N 0.000 claims 1
- QCCRQTSABOKBAV-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)benzimidazol-5-yl]sulfonyl-n,n,2-trimethylpropanamide Chemical compound CC(C)(C)CC1=NC2=CC(S(=O)(=O)C(C)(C)C(=O)N(C)C)=CC=C2N1CC1CC1 QCCRQTSABOKBAV-UHFFFAOYSA-N 0.000 claims 1
- OUFCIVUMOCGGIK-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)benzimidazol-5-yl]sulfonyl-n-(2-hydroxyethyl)-2-methylpropanamide Chemical compound CC(C)(C)CC1=NC2=CC(S(=O)(=O)C(C)(C)C(=O)NCCO)=CC=C2N1CC1CC1 OUFCIVUMOCGGIK-UHFFFAOYSA-N 0.000 claims 1
- VNGXCYILBIPPGB-UHFFFAOYSA-N 2-[3-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-6-yl]sulfonyl-2-methylpropanamide Chemical compound CC(C)(C)CC1=NC2=CC(S(=O)(=O)C(C)(C)C(N)=O)=CN=C2N1CC1CC1 VNGXCYILBIPPGB-UHFFFAOYSA-N 0.000 claims 1
- JLONSMZJMXRVJI-UHFFFAOYSA-N 4-[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)benzimidazol-5-yl]sulfonyloxane-4-carboxamide Chemical compound CC(C)(C)CC1=NC2=CC(S(=O)(=O)C3(CCOCC3)C(N)=O)=CC=C2N1CC1CC1 JLONSMZJMXRVJI-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000000884 Airway Obstruction Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- ITMJWWMXOSSIRK-UHFFFAOYSA-N CC(C)(C)CC1=NC2=C(N1CC3CC3)C=CC(=C2)S(=O)(=O)NC(=O)C4CCC4 Chemical compound CC(C)(C)CC1=NC2=C(N1CC3CC3)C=CC(=C2)S(=O)(=O)NC(=O)C4CCC4 ITMJWWMXOSSIRK-UHFFFAOYSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- JSCLEOGRJVZYPG-UHFFFAOYSA-N [2-[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)benzimidazol-5-yl]sulfonyl-2-methylpropyl]urea Chemical compound CC(C)(C)CC1=NC2=CC(S(=O)(=O)C(C)(C)CNC(N)=O)=CC=C2N1CC1CC1 JSCLEOGRJVZYPG-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- PABDALVXRFWMRT-UHFFFAOYSA-N n-[2-[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)benzimidazol-5-yl]sulfonyl-2-methylpropyl]methanesulfonamide Chemical compound CC(C)(C)CC1=NC2=CC(S(=O)(=O)C(C)(C)CNS(C)(=O)=O)=CC=C2N1CC1CC1 PABDALVXRFWMRT-UHFFFAOYSA-N 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 description 9
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 5
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 4
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77977606P | 2006-03-06 | 2006-03-06 | |
| US79535406P | 2006-04-26 | 2006-04-26 | |
| PCT/IB2007/000474 WO2007102059A1 (en) | 2006-03-06 | 2007-02-23 | Sulfonyl benzimidazole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009536918A JP2009536918A (ja) | 2009-10-22 |
| JP2009536918A5 true JP2009536918A5 (enExample) | 2010-04-02 |
Family
ID=38179500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008557842A Ceased JP2009536918A (ja) | 2006-03-06 | 2007-02-23 | スルホニルベンゾイミダゾール誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7700618B2 (enExample) |
| EP (1) | EP1994011B1 (enExample) |
| JP (1) | JP2009536918A (enExample) |
| AT (1) | ATE484497T1 (enExample) |
| CA (1) | CA2645257C (enExample) |
| DE (1) | DE602007009807D1 (enExample) |
| WO (1) | WO2007102059A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2657247A1 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| WO2008039645A1 (en) | 2006-09-25 | 2008-04-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| US8940900B2 (en) | 2007-02-28 | 2015-01-27 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
| CA2704684A1 (en) | 2007-11-07 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| JP5544299B2 (ja) * | 2007-12-17 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | フルオロアルキル置換ベンズイミダゾールカンナビノイドアゴニスト |
| CA2730037A1 (en) | 2008-07-10 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
| KR20110063485A (ko) | 2008-09-25 | 2011-06-10 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물 |
| EP2379533A4 (en) * | 2009-01-22 | 2012-07-04 | Raqualia Pharma Inc | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFON COMPOUNDS WITH CB2 RECEPTOR AGONIST EFFECT |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| AR076590A1 (es) * | 2009-05-19 | 2011-06-22 | Vivia Biotech Sl | Metodos para proveer pruebas medicinales personalizada ex vivo para neoplasmas hematologicos |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| JP5756800B2 (ja) | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 |
| WO2011037795A1 (en) | 2009-09-22 | 2011-03-31 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
| WO2011057208A2 (en) | 2009-11-06 | 2011-05-12 | Vanderbilt University | Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2011088015A1 (en) | 2010-01-15 | 2011-07-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| AU2011213621A1 (en) | 2010-02-08 | 2012-08-30 | Allergan, Inc. | Pyridazine derivatives useful as cannabinoid - 2 agonists |
| JP5746228B2 (ja) | 2010-03-05 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を選択的に調節するテトラゾール化合物 |
| US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
| WO2012090179A2 (en) | 2010-12-30 | 2012-07-05 | Lupin Limited | Isoquinoline derivatives as cannabinoid receptor modulators |
| WO2012090177A2 (en) | 2010-12-30 | 2012-07-05 | Lupin Limited | Cannabinoid receptor modulators |
| KR20140034798A (ko) | 2011-05-18 | 2014-03-20 | 신젠타 파티서페이션즈 아게 | 아릴티오아세트아미드 유도체에 기반한 살곤충 화합물 |
| WO2013005168A2 (en) | 2011-07-05 | 2013-01-10 | Lupin Limited | Cannabinoid receptor modulators |
| EP2911664B1 (en) | 2012-10-25 | 2019-05-08 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
| WO2014079935A1 (en) | 2012-11-21 | 2014-05-30 | Syngenta Participations Ag | Insecticidal compounds based on arylthioacetamide derivatives |
| ITMI20122221A1 (it) | 2012-12-21 | 2014-06-22 | C4T S C A R L | Nuovi composti del 2,3-diidro-4h-1,3-benzossazin-4-one, metodo per prepararli e forma farmaceutica che li comprende |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| AU2014340182B2 (en) * | 2013-10-22 | 2019-05-23 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| TW201609145A (zh) | 2013-12-25 | 2016-03-16 | 參天製藥股份有限公司 | 注射劑及形成緩釋（ｄｅｐｏｔ）之方法 |
| CA3033079A1 (en) | 2016-08-31 | 2018-03-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
| CN110612289B (zh) * | 2017-03-15 | 2023-06-30 | 住友制药株式会社 | 氘代的苯并咪唑化合物和其医药用途 |
| KR20210070232A (ko) | 2017-07-20 | 2021-06-14 | 아즈테라피즈 인코포레이티드 | 크로몰린 나트륨 및 이부프로펜의 분말화된 제형 |
| WO2019121143A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Substituted cyclopropyl derivatives |
| CA3105392A1 (en) | 2018-07-02 | 2020-01-09 | The General Hospital Corporation | Powdered formulations of cromolyn sodium and .alpha.-lactose |
| EP3893945A4 (en) | 2018-12-10 | 2022-11-30 | The General Hospital Corporation | CROMOGLYC ESTERS AND THEIR USES |
| US12458622B2 (en) | 2020-04-06 | 2025-11-04 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9900625A3 (en) * | 1995-12-28 | 2003-04-28 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives, pharmaceutical compositions containing them and process for preparing the compounds |
| SE0101387D0 (sv) | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | Novel compounds |
| SE0302572D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| ATE417830T1 (de) * | 2004-11-02 | 2009-01-15 | Pfizer | Sulfonylbenzimidazolderivate |
-
2007
- 2007-02-23 WO PCT/IB2007/000474 patent/WO2007102059A1/en not_active Ceased
- 2007-02-23 JP JP2008557842A patent/JP2009536918A/ja not_active Ceased
- 2007-02-23 EP EP07705657A patent/EP1994011B1/en not_active Not-in-force
- 2007-02-23 US US12/280,586 patent/US7700618B2/en not_active Expired - Fee Related
- 2007-02-23 DE DE602007009807T patent/DE602007009807D1/de active Active
- 2007-02-23 CA CA2645257A patent/CA2645257C/en not_active Expired - Fee Related
- 2007-02-23 AT AT07705657T patent/ATE484497T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536918A5 (enExample) | ||
| CA2645257A1 (en) | Sulfonyl benzimidazole derivatives | |
| JP5601422B2 (ja) | ヘテロ環誘導体及び医薬 | |
| US20090239845A1 (en) | Pyrazole compounds as prostaglandin receptors ligands | |
| JP5085659B2 (ja) | Ｌ−ｃｐｔ１阻害剤として有用なインダゾール誘導体 | |
| HRP20171913T1 (hr) | Aminopirimidinilni spojevi kao inhibitori jak | |
| JP2008514643A5 (enExample) | ||
| RS56102B1 (sr) | Derivati pirimidina | |
| CA2586179C (en) | Sulfonyl benzimidazole derivatives | |
| JP2010526793A (ja) | Ｐ２ｘ７調節因子としてのピラゾール誘導体 | |
| JP2009534403A5 (enExample) | ||
| JP2009528989A (ja) | Ｔｌｒ７変調剤としての３−デアザプリン誘導体 | |
| KR20140042848A (ko) | Cb2 작용제로서 유용한 피리딘-2-아미드 | |
| TW200304808A (en) | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | |
| JP2015523353A (ja) | ｍＰＧＥＳ−１阻害剤としてのトリアゾロン化合物 | |
| WO2000047558A1 (en) | Amide compounds and medicinal use thereof | |
| RU2011125314A (ru) | Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в | |
| JP2010510202A5 (enExample) | ||
| CN116745283A (zh) | 用于治疗trpm3介导的病症的杂环衍生物 | |
| MXPA04007736A (es) | Derivados de nicotinamida utiles como inhibidores de pde4. | |
| RS20080118A (sr) | Piridinaminosulfonil supstituisani benzamidi kao inhibitori citohroma p450 3a4 (cyp3a4) | |
| ES2280980T3 (es) | Derivados de nicotinamida utiles como inhibidores de pde4. | |
| JP2006528624A (ja) | Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体 | |
| CN118748993A (zh) | 吲唑化合物和药物 | |
| JP2006169138A (ja) | ピラゾロピリジンピラゾロン誘導体とその付加塩及びｐｄｅ阻害剤 |